Edition:
India

Novo Nordisk A/S (NVO.N)

NVO.N on New York Stock Exchange

33.15USD
1:32am IST
Change (% chg)

$-0.75 (-2.21%)
Prev Close
$33.90
Open
$33.21
Day's High
$33.54
Day's Low
$33.10
Volume
422,653
Avg. Vol
588,559
52-wk High
$57.81
52-wk Low
$30.90

NVO.N

Chart for NVO.N

About

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity... (more)

Overall

Beta: 0.73
Market Cap(Mil.): $68,315.24
Shares Outstanding(Mil.): 2,012.56
Dividend: 0.66
Yield (%): 3.91

Financials

  NVO.N Industry Sector
P/E (TTM): 15.61 28.87 29.67
EPS (TTM): 2.17 -- --
ROI: 75.08 13.62 13.13
ROE: 82.23 14.52 14.27

BRIEF-Denmark's Novo Nordisk will not turn into big M&A machine-CEO

March 23 The CEO of Novo Nordisk's, the world's biggest diabetes company, made the following comments at the firm's annual general meeting on Thursday:

23 Mar 2017

BRIEF-Dong Energy to build biogas plant for Novo Nordisk, Novozymes residues

* Says will in cooperation with Bigadan build a large-scale biogas plant

23 Mar 2017

BRIEF-CVS Health to launch reduced RX

* CVS Health Corp says will launch reduced RX, a prescription savings program that will offer discounts on certain medications

16 Mar 2017

Novo Nordisk's new CEO turns to deals to help revive growth

Novo Nordisk's new chief executive is looking at making acquisitions to broaden the Danish drugmaker's product line-up, in a change of tack that reflects a need for fresh sources of growth at the world's biggest diabetes company.

09 Mar 2017

Novo Nordisk in bid for Global Blood Therapeutics - sources

Danish drugmaker Novo Nordisk A/S has approached Global Blood Therapeutics Inc, a U.S. biotechnology company focused on serious blood disorders, to discuss a potential acquisition, people familiar with the matter said.

08 Mar 2017

Exclusive: Novo Nordisk in bid for Global Blood Therapeutics - sources

Danish drugmaker Novo Nordisk A/S has approached Global Blood Therapeutics Inc , a U.S. biotechnology company focused on serious blood disorders, to discuss a potential acquisition, people familiar with the matter said.

08 Mar 2017

UPDATE 2-Novo Nordisk North American head quits for top job at Falck

* Disappointed to have missed out on top job at Novo (Recasts with comments from Riis)

01 Mar 2017

REFILE-BRIEF-Riis says to head Falck after leaving Novo Nordisk

* Outgoing Novo Nordisk North America head Riis said he taking the role of Chief Executive of Danish emergency services group Falck

01 Mar 2017

Novo Nordisk replaces head of North American operations

COPENHAGEN, March 1 Novo Nordisk, the world's largest insulin maker, said on Wednesday the head of its North American operations Jakob Riis has resigned, casting doubt over its strategy on a market that accounts for about half its sales.

01 Mar 2017

Denmark's Novo raises holding in Evotec to 10.1 pct

FRANKFURT, Feb 28 Denmark's Novo A/S has increased its holding in German biotech group Evotec AG to more than 10 percent, a regulatory filing showed on Tuesday.

28 Feb 2017

More From Around the Web

Competitors

  Price Chg
Sanofi SA (SASY.PA) €83.30 +0.53
Eli Lilly and Co (LLY.N) $84.42 +0.06

Earnings vs. Estimates